Advanced Filters
noise

Menstruation Clinical Trials

A listing of Menstruation medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 86 clinical trials

P Penn Presbyterian Medical Center

A DOUBLE BLIND RANDOMIZED VEHICLE CONTROLLED CROSSOVER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TOPICAL NALOXONE HYDROCHLORIDE LOTION 0.5% FOR THE RELIEF OF PRURITUS IN PATIENTS WITH THE MYCOSIS FUNGOIDES (MF) FORM OF CUTANEOUS T-CELL LYMPHOMA (CTCL

This application is a request to execute a reliance agreement with Chesapeake an external IRB This study is being done to assess the efficacy and safety of Naloxone HCL Lotion 0.5% compared to Vehicle Lotion for the treatment of itching in patients with mycosis fungoides (MF), which is a type …

99 years and younger All Phase 3
P Penn Presbyterian Medical Center

A Phase III multi-center double-blind randomized withdrawal study of LCI699 following a 24 week single-arm open-label dose titration and treatment period to evaluate the safety and efficacy of LCI699 for the treatment of patients with Cushings disease (PRIME)

The study aims to confirm the long-term efficacy and safety of LCI699 for the treatment of patients with Cushing's disease who have had had surgery that has not been successful, or are not a good surgical candidate, or refuse surgery, and have not received radiation treatment for this condition within …

1-99 years All Phase 3
P Penn Presbyterian Medical Center

A Prospective Randomized Double-Blind Placebo-Controlled Crossover Study to Evaluate the Clinical Utility of the Vascular Health Profile Diagnostics Assay (VHP) in Assessment of Response to Administration of a HMG-CoA reductase inhibitor (statin) as Primary Prevention in Patients with Asymptomatic Atherosclerosis

This is a prospective, single-center, randomized double-blind, placebo-controlled, crossover study conducted in the United States (US). Patients will be randomized into two treatment sequences (treatment A in period 1, followed by treatment B in period 2, or treatment B in period 1, followed by treatment A in period 2). At …

1-99 years All
P Penn Presbyterian Medical Center

A Study to Evaluate the Effects of Annovera and Tampon Co-Usage on the Pharmacokinetics of Segesterone Acetate and Ethinyl Estradiol

Normal 0 false false false EN-US X-NONE X-NONE This study involves research about Annovera, an FDA-approved contraceptive vaginal system. The Annovera vaginal system is a ring made of a silicone rubber, which is inserted into your vagina. Annovera contains 2 hormones. One is a progestin called segesterone acetate (SA) and …

18-99 years Female Phase N/A
G Gargi Parikh

Randomized Controlled Trial of Home Therapy with Caffeine Citrate in Moderately Preterm Infants with Apnea of Prematurity

This trial evaluates the effect of continuing treatment with caffeine citrate in the hospital and at home in moderately preterm infants with resolved apnea of prematurity on days of hospitalization after randomization. It is a randomized, double-blinded, placebo-controlled, multicenter trial. The primary outcome of the study will be the number …

99 years and younger All Phase 3
P Penn Presbyterian Medical Center

A multicentre multinational randomised parallel-group placebo-controlled (double blind) and active-controlled (open) trial to compare the efficacy and safety of once weekly dosing of NNC0195-0092 with once weekly dosing of placebo and daily Norditropin FlexPro in adults with growth hormone deficiency for 35 weeks with a 53-week extension period (PRIME)

The trial will compare the efficacy and safety of once weekly dosing of NNC0195-0092 with once weekly dosing of placebo and daily dosing of Norditropin® in adult subjects with growth hormone deficiency.

1-99 years All Phase 3
A ARCHNA BAJAJ

A Phase 2 Randomized Placebo-Controlled Study of Safety and Efficacy Following Repeat-Dose Administration of Evinacumab (anti-ANGPTL3) in Patients with Severe Hypertriglyceridemia (sHTG) at Risk for Acute Pancreatitis

A phase 2, randomized, placebo-controlled study designed to evaluate the efficacy and safety of repeated doses of evinacumab in adult patients with severe hypertriglyceridemia. The study consists of screening period (up to 37 days), a baseline/single-blind placebo run in period, a 12-week double-blind treatment period, a single-blind 12 week treatment …

99 years and younger All Phase 2
P Penn Presbyterian Medical Center

AN EXPLORATORY OPEN-LABEL PROOF-OF-CONCEPT PHASE 2A STUDY OF MAVACAMTEN (MYK-461) IN PARTICIPANTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFpEF) AND CHRONIC ELEVATION OF CARDIAC TROPONIN I AND/OR NT-PROBNP

This is a multicenter, exploratory, open-label study to explore the efficacy and/or pharmacodynamic effect, PK, safety, and tolerability of mavacamten in approximately 35 ambulatory participants with symptomatic HFpEF and elevated cTnI and/or elevated NT-proBNP as defined in inclusion/exclusion criteria. The study will include an up to 7-week screening period (with …

99 years and younger All Phase 2
T Tanyra Smith

North American Registry for Care and Research in MS - NARCRMS

NARCRMS is a national database that collects patient and physician-based information on MS and will bring together information and data collected in multiple registries and databases across the U.S. and Canada. We expect that data collected consistently over long periods of time, when carefully studied, will 1) produce new clues …

18-50 years All
E EMILE MOHLER

A Phase 2 Multi-center Randomized Double-Blind Placebo-Controlled Dose Range Finding Study to Evaluate the Safety Hemodynamic Effects and Efficacy of Intramuscular Injection of Human Placenta-Derived Cells (PDA-002) in Subjects who have Diabetic Foot Ulcer with Peripheral Arterial Disease

This is a Phase 2, randomized, double-blind, placebo-controlled, dose range finding study in subjects who have DFU with PAD. The study will enroll approximately 24 subjects. Two dose levels of PDA-002 (3 x 106 and 30 x 106 cells) versus placebo will be evaluated in 1:1:1 randomization approach. Subjects will …

1-99 years All Phase 2

Simplify language using AI